The FDA greenlights treatment-related changes in bone mineral density as a surrogate endpoint in anti-osteoporosis drug trials in postmenopausal women.

FDA qualification of Total Hip BMD as a validated surrogate endpoint for novel osteoporosis drug development further bolsters ...

For decades, osteoporosis has meant a slow, one way slide toward fragile bones and fracture risk, managed but rarely truly ...

Starting an incretin receptor agonist -- especially tirzepatide (Mounjaro, Zepbound) -- was associated with reduced risks of ...

The analysis, published in The Lancet Healthy Longevity, concluded there was “n o significant association” between HRT and ...

Medicare doesn’t provide services entirely "for free," but some items and services are covered with no out-of-pocket costs ...

The average age of menopause is around 45, and it can bring weight gain and cognitive shifts. Preparing before this phase can help manage these effects.

Researchers said there was “no evidence that” using hormone therapy “either increases or decreases the risk of dementia in ...

Through a recent notice, the Undergraduate Medical Education Board (UGMEB) of the National Medical Commission (NMC) has ...

Imposing the tax on virtual assets is a measure that appears to have no legal, economic or statistical basis, one expert told ITR ...

I have suffered from high blood pressure since I was a young man in my early 20s. I recently turned 70 years old. My blood pressure has ...

UPF scientists have discovered this 7% of critical areas based on their pioneering analysis model that allows minimizing the ...